Patents
Publications
News 2011
News 2010
|
NEWS AND EVENTS 2009 ARCHIVE
November 2009:
Oncolix's CEO,
Michael Redman will be delivering a corporate presentation at Texas Life
Science Conference 2009.
The conference will be held November 11 - 13, 2009
at the The Brown Foundation Institute of Molecular Medicine in Houston, Texas. |
 |
October 2009:
Oncolix's CEO, Michael
Redman will be delivering a corporate presentation at the 2009 Life
Sciences and Healthcare Venture Summit, being held on October 27,
2009 in New York City. |
 |
September 2009:
Oncolix's CEO,
Michael Redman delivered a corporate presentation at BioPharm America™
2009.
The conference was held September 16 - 18, 2009 in San
Francisco, California.
Oncolix's CEO, Michael Redman delivered a
corporate presentation Rodman & Renshaw's 11th Annual Healthcare
Conference. The conference will be held September 9-11, 2009, at the Palace
Hotel in New York City.
|
 |
|
June 2009:
Dr. Wen Chen's group
presented two abstracts at the Endocrine Society’s Annual Meeting, Washington,
DC, June 10 – 13, 2009.
In vivo evidence of prolactin receptor antagonist, Prolanta™ (G129R), in
inhibition of HER2/neu tumor. In vitro and in vivo data indicating prolactin
receptor antagonist, Prolanta™ (G129R), suppressed mammary tumor stem cell
populations measured by ALDH1 activity.
|
 |
January 2009:
Oncolix's CEO, Michael
Redman presented at the Biotech Showcase 2009 San Francisco, CA, January 14,
2009. |
|
June 2007:
Dr.
Wen Chen's group presented two abstracts at the Endocrine Society’s Annual
Meeting, Toronto, Canada, June 2-5, 2007.
A multifaceted, targeted, combination
therapy using three novel prolactin receptor antagonists.
Development of novel ligands that activate Jak2/Stat5 signaling exclusively
through the heterodimer of a human prolactin receptor and a human growth
hormone receptor.
|
 |
| | |